# Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer

> **NCT01242449** · PHASE2 · COMPLETED · sponsor: **Vejle Hospital** · enrollment: 10 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT01242449
- **Lead sponsor:** Vejle Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-10
- **Final completion:** 2014-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2015-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01242449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01242449, "Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01242449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*